This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
This week, we will discuss the VALIANT study, pegcetacoplan in C3G and IC MPGN.
2025 was rich in successful stories. Here are the top 10 that impressed our audience.
SGLT2i have reshaped cardiorenal care, but kidney transplant recipients have mostly been left out of the story. INFINITI starts to close that gap, testing the safety and physiology of dapagliflozin in stable KTR.
Do #flozins behave the same in transplanted kidneys? Check out the VA by Janany Sabescumar
Los iSGLT2 han revolucionado la protección cardiorrenal, pero los trasplantados renales han quedado fuera de la historia. El ensayo INFINITI empieza a cerrar esa brecha. ¿Flozinaran igual los iSGLT2 en el riñón trasplantado? Revisa el resumen visual creado por Janany Sabescumar
Can pushing K⁺ to the high-normal range reduce ICD shocks and hospitalizations? POTCAST challenges our fear of potassium.
Check out the VA by Jeyakumar Meyyappan and join the #NephJC conversation
Check out VALIANT recap: a 26-week analysis of the phase 3 trial of pegcetacoplan in C3GN! Thread by NephJC intern Bogdan Agavriloaei.
1/10 Last #NephJC we discussed pegcetacoplan in C3 glomerulopathy and Immune-Complex MPGN #TenPostNephJC
— Nephrology Journal Club (@NephJC) January 16, 2026
Given the central role of complement dysregulation in C3GN, the 🔑 question was whether 🎯 complement inhibition could deliver clinical benefithttps://t.co/1GyC3P8emi pic.twitter.com/Hllq7tEJaG
The VALIANT phase 3 RCT shows that proximal C3 inhibition with pegcetacoplan leads to a significantly greater reduction in proteinuria compared with placebo in patients with C3G and primary immune-complex MPGN. This trial builds on prior upstream complement strategies and strengthens the case for disease-targeted therapy in C3G.
Check out the VA Dr. Akshaya Jayachandran and don´t forget to join #NephJC on bluesky.
Check out PISCES recap: a whale of a tale of fish oil and cardio-protection in ESRD! Thread by NephJC intern Sai Vani
Check out ORIGIN 3 recap: a 36-week, interim analysis of phase 3 trial of atacicept in IgAN! Thread by NephJC intern Marc Soco.
1/10 Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
— Nephrology Journal Club (@NephJC) November 24, 2025
Read the @NEJM article 👇 https://t.co/yBMbZtb7XG pic.twitter.com/6vp0tROznZ
ORIGIN-3 ha llegado a NephJC con atacicept en NIgA.
Un paso sólido hacia una terapia dirigida anti BAFF/APRIL, que aborda la fisiopatología desde su origen. ¡Las señales tempranas son prometedoras!
Revisa el resumen visual realizado por Clemens Weber
A thread on the most relevant part of the chat on tolerance induction in HLA-matched transplant with donor hematopoietic stem cells (MDR-101). Thread by Akshaya Jayachandran.
